The two models had similar concentrations of doxorubicin in the plasma, liver, and spleen, but the ratio of tumor to plasma AUC0–96h of PLD was much higher in the SKOV-3 model than in the HEC1A model leading to a better survival benefit when using PLD in the SKOV-3 model [123]. This evidence concerns the gene GPLD1 and neoplasm.